{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T08:33:06Z","timestamp":1792053186511,"version":"4.4.0"},"reference-count":155,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ctrv.2026.103125","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T07:28:13Z","timestamp":1774682893000},"page":"103125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Neoantigen-based dendritic cell vaccines in lung cancer: overcoming immunosuppressive barriers for durable antitumor immunity"],"prefix":"10.1016","volume":"145","author":[{"given":"Zhang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhang","family":"Feiyue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huang","family":"Luyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhang","family":"Wenqiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3940-4630","authenticated-orcid":false,"given":"Jens-C","family":"Rueckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10454","key":"10.1016\/j.ctrv.2026.103125_b0005","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0140-6736(24)01029-8","article-title":"New promises and challenges in the treatment of advanced non-small-cell lung cancer","volume":"404","author":"Meyer","year":"2024","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103125_b0010","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13045-020-00881-7","article-title":"Emerging therapeutic agents for advanced non-small cell lung cancer","volume":"13","author":"Chen","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103125_b0015","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/s41551-019-0436-x","article-title":"Engineering patient-specific cancer immunotherapies","volume":"3","author":"Scheetz","year":"2019","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.ctrv.2026.103125_b0020","article-title":"Hyperprogressive disease in non-small cell lung cancer after PD-1\/PD-L1 inhibitors immunotherapy: underlying killer","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103125_b0025","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1038\/s41467-021-22801-0","article-title":"Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer","volume":"12","author":"Wu","year":"2021","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103125_b0030","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.immuni.2019.03.009","article-title":"Single-cell transcriptomics of human and mouse lung cancers reveals conserved myeloid populations across individuals and species","volume":"50","author":"Zilionis","year":"2019","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103125_b0035","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13045-020-00939-6","article-title":"Dendritic cell biology and its role in tumor immunotherapy","volume":"13","author":"Wang","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103125_b0040","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.chest.2016.09.030","article-title":"Dendritic cells in human lung disease: recent advances","volume":"151","author":"Upham","year":"2017","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103125_b0045","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41423-018-0005-3","article-title":"Chemokine and chemotactic signals in dendritic cell migration","volume":"15","author":"Tiberio","year":"2018","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103125_b0050","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1038\/s41467-018-05032-8","article-title":"A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers","volume":"9","author":"Gettinger","year":"2018","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103125_b0055","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/cr.2016.149","article-title":"Innate immune signaling and regulation in cancer immunotherapy","volume":"27","author":"Corrales","year":"2017","journal-title":"Cell Res"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103125_b0060","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000832","article-title":"Skin dendritic cells in melanoma are key for successful checkpoint blockade therapy","volume":"9","author":"Prokopi","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103125_b0065","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/nm.4200","article-title":"Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses","volume":"22","author":"Moynihan","year":"2016","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103125_b0070","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","article-title":"Dendritic cells in cancer immunology and immunotherapy","volume":"20","author":"Wculek","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ctrv.2026.103125_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2021.101481","article-title":"The role of dendritic cells in cancer and anti-tumor immunity","volume":"52","author":"Marciscano","year":"2021","journal-title":"Semin Immunol"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103125_b0080","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/s41571-025-01035-9","article-title":"The next generation of immunotherapies for lung cancers","volume":"22","author":"Zhao","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103125_b0085","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41571-024-00979-8","article-title":"Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions","volume":"22","author":"Wang","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103125_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101563","article-title":"Lung cancer and oncolytic virotherapy\u2013enemy's enemy","volume":"27","author":"Li","year":"2023","journal-title":"Transl Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103125_b0095","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13046-018-0751-1","article-title":"The perfect personalized cancer therapy: cancer vaccines against neoantigens","volume":"37","author":"Aurisicchio","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103125_b0100","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.trecan.2023.02.004","article-title":"Neoantigen-directed therapeutics in the clinic: where are we?","volume":"9","author":"Lybaert","year":"2023","journal-title":"Trends Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103125_b0105","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","article-title":"Advances in the development of personalized neoantigen-based therapeutic cancer vaccines","volume":"18","author":"Blass","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"suppl_12","key":"10.1016\/j.ctrv.2026.103125_b0110","doi-asserted-by":"crossref","first-page":"xii11","DOI":"10.1093\/annonc\/mdx681","article-title":"Preclinical and clinical development of neoantigen vaccines","volume":"28","author":"Li","year":"2017","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103125_b0115","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1093\/annonc\/mdv382","article-title":"Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era","volume":"26","author":"Martin","year":"2015","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103125_b0120","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1158\/2159-8290.CD-20-1285","article-title":"Resolving the spatial and cellular architecture of lung adenocarcinoma by multiregion single-cell sequencing","volume":"11","author":"Sinjab","year":"2021","journal-title":"Cancer Discov"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103125_b0125","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/j.immuni.2021.08.026","article-title":"Conventional type I dendritic cells maintain a reservoir of proliferative tumor-antigen specific TCF-1(+) CD8(+) Tcells in tumor-draining lymph nodes","volume":"54","author":"Schenkel","year":"2021","journal-title":"Immunity"},{"issue":"suppl_12","key":"10.1016\/j.ctrv.2026.103125_b0130","doi-asserted-by":"crossref","first-page":"xii44","DOI":"10.1093\/annonc\/mdx237","article-title":"Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy","volume":"28","author":"S\u00e1nchez-Paulete","year":"2017","journal-title":"Ann Oncol"},{"issue":"7822","key":"10.1016\/j.ctrv.2026.103125_b0135","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41586-020-2611-3","article-title":"cDC1 prime and are licensed by CD4(+) T cells to induce anti-tumour immunity","volume":"584","author":"Ferris","year":"2020","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103125_b0140","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.it.2021.10.004","article-title":"Type 1 conventional dendritic cells: ontogeny, function, and emerging roles in cancer immunotherapy","volume":"42","author":"Zhang","year":"2021","journal-title":"Trends Immunol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103125_b0145","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000474","article-title":"Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103(+) conventional dendritic cells","volume":"8","author":"Zhou","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103125_b0150","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ccell.2014.09.007","article-title":"Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity","volume":"26","author":"Broz","year":"2014","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103125_b0155","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1038\/s41467-020-16164-1","article-title":"Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma","volume":"11","author":"Kim","year":"2020","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103125_b0160","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/jnci\/djab157","article-title":"Clinical implications of inter- and intratumor heterogeneity of immune cell markers in lung cancer","volume":"114","author":"Zhao","year":"2022","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103125_b0165","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s00018-016-2317-8","article-title":"Molecular mechanisms involved in dendritic cell dysfunction in cancer","volume":"74","author":"Tang","year":"2017","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.ctrv.2026.103125_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104980","article-title":"Tumor microenvironment-related dendritic cell deficiency: a target to enhance tumor immunotherapy","volume":"159","author":"Zhu","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.ctrv.2026.103125_b0175","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.pharmthera.2016.04.003","article-title":"State-of-the-art of regulatory dendritic cells in cancer","volume":"164","author":"Conejo-Garcia","year":"2016","journal-title":"Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103125_b0180","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1093\/annonc\/mdz207","article-title":"Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer","volume":"30","author":"Kudo","year":"2019","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103125_b0185","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40880-019-0387-3","article-title":"Impaired dendritic cell functions in lung cancer: a review of recent advances and future perspectives","volume":"39","author":"Wang","year":"2019","journal-title":"Cancer Commun (Lond)"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103125_b0190","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s43018-022-00338-5","article-title":"The interaction of CD4(+) helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response","volume":"3","author":"Cohen","year":"2022","journal-title":"Nat Cancer"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103125_b0195","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41587-020-0442-2","article-title":"Dissecting cellular crosstalk by sequencing physically interacting cells","volume":"38","author":"Giladi","year":"2020","journal-title":"Nat Biotechnol"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103125_b0200","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.immuni.2023.01.010","article-title":"Tissue-specific abundance of interferon-gamma drives regulatory Tcells to restrain DC1-mediated priming of cytotoxic Tcells against lung cancer","volume":"56","author":"Zagorulya","year":"2023","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103125_b0205","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.immuni.2023.06.003","article-title":"CXCR3 expression in regulatory Tcells drives interactions with type I dendritic cells in tumors to restrict CD8(+) Tcell antitumor immunity","volume":"56","author":"Moreno Ayala","year":"2023","journal-title":"Immunity"},{"issue":"699","key":"10.1016\/j.ctrv.2026.103125_b0210","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adh8005","article-title":"Tumor-associated fibrosis impairs immune surveillance and response to immune checkpoint blockade in non-small cell lung cancer","volume":"15","author":"Herzog","year":"2023","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103125_b0215","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1038\/s41467-019-09370-z","article-title":"Wnt1 silences chemokine genes in dendritic cells and induces adaptive immune resistance in lung adenocarcinoma","volume":"10","author":"Kerdidani","year":"2019","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103125_b0220","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.immuni.2023.05.011","article-title":"Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer Tcell responses","volume":"56","author":"Bayerl","year":"2023","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103125_b0225","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1158\/0008-5472.CAN-17-1307","article-title":"Downregulation of membrane trafficking proteins and lactate conditioning determine loss of dendritic cell function in lung cancer","volume":"78","author":"Caronni","year":"2018","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103125_b0230","doi-asserted-by":"crossref","first-page":"6623","DOI":"10.1038\/s41467-022-34428-w","article-title":"Tumor factors stimulate lysosomal degradation of tumor antigens and undermine their cross-presentation in lung cancer","volume":"13","author":"Lu","year":"2022","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103125_b0235","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.immuni.2021.10.020","article-title":"Type I interferon activates MHC class I-dressed CD11b(+) conventional dendritic cells to promote protective anti-tumor CD8(+) Tcell immunity","volume":"55","author":"Duong","year":"2022","journal-title":"Immunity"},{"issue":"561","key":"10.1016\/j.ctrv.2026.103125_b0240","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba5464","article-title":"Interleukin-2 signals converge in a lymphoid-dendritic cell pathway that promotes anticancer immunity","volume":"12","author":"Raeber","year":"2020","journal-title":"Sci Transl Med"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103125_b0245","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.ccell.2019.05.005","article-title":"Targeting tumors with IL-10 prevents dendritic cell-mediated CD8(+) T cell apoptosis","volume":"35","author":"Qiao","year":"2019","journal-title":"Cancer Cell"},{"issue":"7802","key":"10.1016\/j.ctrv.2026.103125_b0250","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41586-020-2134-y","article-title":"A conserved dendritic-cell regulatory program limits antitumour immunity","volume":"580","author":"Maier","year":"2020","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103125_b0255","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.ccell.2020.05.002","article-title":"Visualizing synaptic transfer of tumor antigens among dendritic cells","volume":"37","author":"Ruhland","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2026.103125_b0260","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1146\/annurev-immunol-041015-055700","article-title":"Antigen presentation by extracellular vesicles from professional antigen-presenting cells","volume":"36","author":"Lindenbergh","year":"2018","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103125_b0265","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1038\/s41467-022-31218-2","article-title":"Cancer cells dying from ferroptosis impede dendritic cell-mediated anti-tumor immunity","volume":"13","author":"Wiernicki","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2026.103125_b0270","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.arr.2017.07.002","article-title":"Modulation of dendritic cell and T cell cross-talk during aging: the potential role of checkpoint inhibitory molecules","volume":"38","author":"Gardner","year":"2017","journal-title":"Ageing Res Rev"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103125_b0275","article-title":"Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent","volume":"12","author":"Zhu","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ctrv.2026.103125_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117580","article-title":"Dendritic cell therapy in cancer treatment; the state-of-the-art","volume":"254","author":"Sadeghzadeh","year":"2020","journal-title":"Life Sci"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103125_b0285","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41573-020-0074-8","article-title":"Antitumour dendritic cell vaccination in a priming and boosting approach","volume":"19","author":"Harari","year":"2020","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103125_b0290","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12943-019-1055-6","article-title":"Neoantigen vaccine: an emerging tumor immunotherapy","volume":"18","author":"Peng","year":"2019","journal-title":"Mol Cancer"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103125_b0295","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jtho.2021.01.1624","article-title":"The current lung cancer neoantigen landscape and implications for therapy","volume":"16","author":"Ye","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103125_b0300","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41588-018-0283-9","article-title":"Accounting for proximal variants improves neoantigen prediction","volume":"51","author":"Hundal","year":"2019","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103125_b0305","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41591-020-01206-4","article-title":"Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma","volume":"27","author":"Hu","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103125_b0310","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13045-019-0787-5","article-title":"Tumor neoantigens: from basic research to clinical applications","volume":"12","author":"Jiang","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103125_b0315","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1016\/j.immuni.2023.09.002","article-title":"Machine learning methods and harmonized datasets improve immunogenic neoantigen prediction","volume":"56","author":"M\u00fcller","year":"2023","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103125_b0320","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1021\/acsnano.8b07371","article-title":"Surgical tumor-derived personalized photothermal vaccine formulation for cancer immunotherapy","volume":"13","author":"Ye","year":"2019","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103125_b0325","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010993","article-title":"Utilization of primary tumor samples for cancer neoantigen discovery","volume":"13","author":"Leko","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"7912","key":"10.1016\/j.ctrv.2026.103125_b0330","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41586-022-04696-z","article-title":"Fundamental immune-oncogenicity trade-offs define driver mutationfitness","volume":"606","author":"Hoyos","year":"2022","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103125_b0335","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002531","article-title":"Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations","volume":"9","author":"Li","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103125_b0340","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.jtho.2015.11.006","article-title":"Identification of individual cancer-specific somatic mutations for neoantigen-based immunotherapy of lung cancer","volume":"11","author":"Karasaki","year":"2016","journal-title":"J Thorac Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103125_b0345","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.cell.2017.01.014","article-title":"Applications of immunogenomics to cancer","volume":"168","author":"Liu","year":"2017","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103125_b0350","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1172\/JCI99538","article-title":"Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors","volume":"129","author":"Chen","year":"2019","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103125_b0355","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1158\/2159-8290.CD-17-1418","article-title":"Combined analysis of antigen presentation and T-cell recognition reveals restricted immune responses in melanoma","volume":"8","author":"Kalaora","year":"2018","journal-title":"Cancer Discov"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103125_b0360","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/nbt.3344","article-title":"Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes","volume":"33","author":"Shukla","year":"2015","journal-title":"Nat Biotechnol"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103125_b0365","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1158\/0008-5472.CAN-24-0565","article-title":"Personalized cancer vaccines directed against tumor mutations: building evidence from mice to humans","volume":"84","author":"Fritsch","year":"2024","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103125_b0370","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007180","article-title":"Single-cell sequencing on CD8(+) TILs revealed the nature of exhausted T cells recognizing neoantigen and cancer\/testis antigen in non-small cell lung cancer","volume":"11","author":"Komuro","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103125_b0375","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ccell.2022.03.012","article-title":"A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers","volume":"40","author":"Hanada","year":"2022","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103125_b0380","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1158\/2159-8290.CD-20-0377","article-title":"An empirical antigen selection method identifies neoantigens that either elicit broad antitumor T-cell responses or drive tumor growth","volume":"11","author":"Lam","year":"2021","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103125_b0385","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41392-020-00448-5","article-title":"Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer","volume":"6","author":"Ding","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.ctrv.2026.103125_b0390","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13046-016-0295-1","article-title":"Eliciting cytotoxic T lymphocytes against human laryngeal cancer-derived antigens: evaluation of dendritic cells pulsed with a heat-treated tumor lysate and other antigen-loading strategies for dendritic-cell-based vaccination","volume":"35","author":"Wei","year":"2016","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103125_b0395","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.lungcan.2007.04.002","article-title":"Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells","volume":"57","author":"Hirschowitz","year":"2007","journal-title":"Lung Cancer"},{"issue":"14","key":"10.1016\/j.ctrv.2026.103125_b0400","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1200\/JCO.2004.01.074","article-title":"Autologous dendritic cell vaccines for non-small-cell lung cancer","volume":"22","author":"Hirschowitz","year":"2004","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103125_b0405","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.annonc.2020.05.008","article-title":"Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO Precision Medicine Working Group","volume":"31","author":"De Mattos-Arruda","year":"2020","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103125_b0410","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003821","article-title":"Targeting the tumor mutanome for personalized vaccination in a TMB low non-small cell lung cancer","volume":"10","author":"McCann","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103125_b0415","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.cell.2020.09.015","article-title":"Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction","volume":"183","author":"Wells","year":"2020","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103125_b0420","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13073-019-0679-x","article-title":"pTuneos: prioritizing tumor neoantigens from next-generation sequencing data","volume":"11","author":"Zhou","year":"2019","journal-title":"Genome Med"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103125_b0425","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ccr.2010.11.011","article-title":"Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression","volume":"19","author":"DuPage","year":"2011","journal-title":"Cancer Cell"},{"issue":"10499","key":"10.1016\/j.ctrv.2026.103125_b0430","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0140-6736(25)00553-7","article-title":"Cancer vaccines and the future of immunotherapy","volume":"406","author":"Pail","year":"2025","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103125_b0435","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrc.2016.154","article-title":"Targeting neoantigens to augment antitumour immunity","volume":"17","author":"Yarchoan","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103125_b0440","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1038\/s41467-024-46685-y","article-title":"Dendritic cell-targeted therapy expands CD8 T cell responses to bona-fide neoantigens in lung tumors","volume":"15","author":"L\u00f3pez","year":"2024","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103125_b0445","article-title":"Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived Tcells exhibiting the full differentiation spectrum","volume":"5","author":"Ingels","year":"2024","journal-title":"Cell Rep Med"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103125_b0450","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jcyt.2018.06.006","article-title":"An accelerated, clinical-grade protocol to generate high yields of type 1-polarizing messenger RNA-loaded dendritic cells for cancer vaccination","volume":"20","author":"Brabants","year":"2018","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103125_b0455","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1038\/s41467-021-22308-8","article-title":"Bioengineered bacteria-derived outer membrane vesicles as a versatile antigen display platform for tumor vaccination via Plug-and-Display technology","volume":"12","author":"Cheng","year":"2021","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103125_b0460","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s43018-022-00352-7","article-title":"Concurrent delivery of immune checkpoint blockade modulates T cell dynamics to enhance neoantigen vaccine-generated antitumor immunity","volume":"3","author":"Liu","year":"2022","journal-title":"Nat Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103125_b0465","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/s13046-020-01781-x","article-title":"Dexosomes as a cell-free vaccine for cancer immunotherapy","volume":"39","author":"Nikfarjam","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103125_b0470","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jconrel.2022.11.053","article-title":"Dendritic cell derived exosomes loaded neoantigens for personalized cancer immunotherapies","volume":"353","author":"Li","year":"2023","journal-title":"J Control Release"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103125_b0475","doi-asserted-by":"crossref","first-page":"633","DOI":"10.7150\/ijbs.38414","article-title":"Tumor Cell-associated exosomes robustly elicit anti-tumor immune responses through modulating dendritic cell vaccines in lung tumor","volume":"16","author":"Wang","year":"2020","journal-title":"Int J Biol Sci"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103125_b0480","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003564","article-title":"Peptidic microarchitecture-trapped tumor vaccine combined with immune checkpoint inhibitor or PI3K\u03b3 inhibitor can enhance immunogenicity and eradicate tumors","volume":"10","author":"Du","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2026.103125_b0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.120844","article-title":"Personalized combination nano-immunotherapy for robust induction and tumor infiltration of CD8(+) T cells","volume":"274","author":"Park","year":"2021","journal-title":"Biomaterials"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103125_b0490","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1039\/D3CS00162H","article-title":"Advancing nanotechnology for neoantigen-based cancer theranostics","volume":"53","author":"Zou","year":"2024","journal-title":"Chem Soc Rev"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103125_b0495","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202209910","article-title":"Acid-ionizable iron nanoadjuvant augments STING activation for personalized vaccination immunotherapy of cancer","volume":"35","author":"Chen","year":"2023","journal-title":"Adv Mater"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103125_b0500","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/s41587-019-0390-x","article-title":"Peptide-TLR-7\/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens","volume":"38","author":"Lynn","year":"2020","journal-title":"Nat Biotechnol"},{"issue":"24","key":"10.1016\/j.ctrv.2026.103125_b0505","article-title":"Sulfonium-stapled peptides-based Neoantigen delivery system for personalized tumor immunotherapy and prevention","volume":"11","author":"Zhang","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.ctrv.2026.103125_b0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2024.101254","article-title":"Are we getting closer to a successful neoantigen cancer vaccine?","volume":"96","author":"Manoutcharian","year":"2024","journal-title":"Mol Aspects Med"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103125_b0515","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1158\/0008-5472.CAN-23-2042","article-title":"Targeting tumor heterogeneity with neoantigen-based cancer vaccines","volume":"84","author":"Pounraj","year":"2024","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103125_b0520","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1158\/2159-8290.CD-17-0256","article-title":"TCR Repertoire intratumor heterogeneity in localized lung adenocarcinomas: an association with predicted neoantigen heterogeneity and postsurgical recurrence","volume":"7","author":"Reuben","year":"2017","journal-title":"Cancer Discov"},{"issue":"7681","key":"10.1016\/j.ctrv.2026.103125_b0525","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nature24473","article-title":"A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy","volume":"551","author":"\u0141uksza","year":"2017","journal-title":"Nature"},{"issue":"7706","key":"10.1016\/j.ctrv.2026.103125_b0530","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/s41586-018-0130-2","article-title":"Bystander CD8(+) T cells are abundant and phenotypically distinct in human tumour infiltrates","volume":"557","author":"Simoni","year":"2018","journal-title":"Nature"},{"issue":"6280","key":"10.1016\/j.ctrv.2026.103125_b0535","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103125_b0540","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1898832","article-title":"Antitumor efficacy of a neoantigen cancer vaccine delivered by electroporation is influenced by microbiota composition","volume":"10","author":"Lione","year":"2021","journal-title":"Oncoimmunology"},{"issue":"35","key":"10.1016\/j.ctrv.2026.103125_b0545","article-title":"Maximizing efficacy of cancer nanovaccines and immune cells landscape in responders and non-responders to immunotherapy","volume":"12","author":"Xu","year":"2025","journal-title":"Adv Sci (Weinh)"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103125_b0550","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ccell.2023.12.013","article-title":"Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer","volume":"42","author":"Memon","year":"2024","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103125_b0555","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009126","article-title":"Spatial colocalization and combined survival benefit of natural killer and CD8 T cells despite profound MHC class I loss in non-small cell lung cancer","volume":"12","author":"Wessel","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"7738","key":"10.1016\/j.ctrv.2026.103125_b0560","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","article-title":"Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial","volume":"565","author":"Keskin","year":"2019","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103125_b0565","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002865","article-title":"High-dose IL-2\/CD25 fusion protein amplifies vaccine-induced CD4(+) and CD8(+) neoantigen-specific T cells to promote antitumor immunity","volume":"9","author":"Hernandez","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103125_b0570","article-title":"Neoantigen-specific Tcell help outperforms non-specific help in multi-antigen DNA vaccination against cancer","volume":"32","author":"de Graaf","year":"2024","journal-title":"Mol Ther Oncol"},{"issue":"23","key":"10.1016\/j.ctrv.2026.103125_b0575","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.174027","article-title":"CD4 T cell-activating neoantigens enhance personalized cancer vaccine efficacy","volume":"8","author":"Huff","year":"2023","journal-title":"JCI Insight"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103125_b0580","article-title":"Mitochondrial DNA-boosted dendritic cell-based nanovaccination triggers antitumor immunity in lung and pancreatic cancers","volume":"5","author":"Shang","year":"2024","journal-title":"Cell Rep Med"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103125_b0585","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1158\/1535-7163.MCT-24-0435","article-title":"Characteristics of a CCL21 gene-modified dendritic cell vaccine utilized for a clinical trial in non-small cell lung cancer","volume":"24","author":"Oh","year":"2025","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2026.103125_b0590","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121706","article-title":"MnO(2)-melittin nanoparticles serve as an effective anti-tumor immunotherapy by enhancing systemic immune response","volume":"288","author":"Tang","year":"2022","journal-title":"Biomaterials"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103125_b0595","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41422-020-00395-4","article-title":"Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy","volume":"30","author":"Lv","year":"2020","journal-title":"Cell Res"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103125_b0600","doi-asserted-by":"crossref","DOI":"10.1172\/JCI166031","article-title":"Glycolysis drives STING signaling to facilitate dendritic cell antitumor function","volume":"133","author":"Hu","year":"2023","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103125_b0605","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001966","article-title":"Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy","volume":"9","author":"Hubert","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"7550","key":"10.1016\/j.ctrv.2026.103125_b0610","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nature14424","article-title":"Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity","volume":"521","author":"Carmi","year":"2015","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103125_b0615","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41551-021-00834-6","article-title":"Systemic immune responses to irradiated tumours via the transport of antigens to the tumour periphery by injected flagellate bacteria","volume":"6","author":"Wang","year":"2022","journal-title":"Nat Biomed Eng"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103125_b0620","first-page":"2971","article-title":"Immunotherapy of autologous tumor lysate-loaded dendritic cell vaccines by a closed-flow electroporation system for solid tumors","volume":"33","author":"Kamigaki","year":"2013","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103125_b0625","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13045-023-01457-x","article-title":"Clinical development of mRNA therapies against solid tumors","volume":"16","author":"Wu","year":"2023","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ctrv.2026.103125_b0630","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jconrel.2017.03.028","article-title":"Optimized biodegradable polymeric reservoir-mediated local and sustained co-delivery of dendritic cells and oncolytic adenovirus co-expressing IL-12 and GM-CSF for cancer immunotherapy","volume":"259","author":"Oh","year":"2017","journal-title":"J Control Release"},{"issue":"26","key":"10.1016\/j.ctrv.2026.103125_b0635","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2015.66.3955","article-title":"Efficacy of tumor vaccines and cellular immunotherapies in non-small-cell lung cancer: a systematic review and meta-analysis","volume":"34","author":"Dammeijer","year":"2016","journal-title":"J Clin Oncol"},{"issue":"534","key":"10.1016\/j.ctrv.2026.103125_b0640","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav7431","article-title":"Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy","volume":"12","author":"Mayoux","year":"2020","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103125_b0645","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.1038\/s41467-020-18570-x","article-title":"PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade","volume":"11","author":"Peng","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103125_b0650","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13046-022-02289-2","article-title":"ROR\u03b3t agonist enhances anti-PD-1 therapy by promoting monocyte-derived dendritic cells through CXCL10 in cancers","volume":"41","author":"Xia","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"issue":"16","key":"10.1016\/j.ctrv.2026.103125_b0655","doi-asserted-by":"crossref","first-page":"4556","DOI":"10.1158\/1078-0432.CCR-16-2821","article-title":"Phase I trial of intratumoral injection of CCL21 gene-modified dendritic cells in lung cancer elicits tumor-specific immune responses and CD8(+) T-cell infiltration","volume":"23","author":"Lee","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"30","key":"10.1016\/j.ctrv.2026.103125_b0660","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2025570118","article-title":"Characterization of neoantigen-specific T cells in cancer resistant to immune checkpoint therapies","volume":"118","author":"Li","year":"2021","journal-title":"PNAS"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103125_b0665","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41551-024-01285-5","article-title":"Antitumour vaccination via the targeted proteolysis of antigens isolated from tumour lysates","volume":"9","author":"Zhao","year":"2025","journal-title":"Nat Biomed Eng"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103125_b0670","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s00262-023-03598-x","article-title":"Personalized neoantigen vaccine enhances the therapeutic efficacy of bevacizumab and anti-PD-1 antibody in advanced non-small cell lung cancer","volume":"73","author":"Lin","year":"2024","journal-title":"Cancer Immunol Immunother"},{"issue":"6230","key":"10.1016\/j.ctrv.2026.103125_b0675","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103125_b0680","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/s40425-019-0695-9","article-title":"Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment","volume":"7","author":"Fehlings","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"8056","key":"10.1016\/j.ctrv.2026.103125_b0685","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/s41586-025-08586-y","article-title":"Clonal driver neoantigen loss under EGFR TKI and immune selection pressures","volume":"639","author":"Al Bakir","year":"2025","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103125_b0690","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1038\/s43018-023-00591-2","article-title":"ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer","volume":"4","author":"Mota","year":"2023","journal-title":"Nat Cancer"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103125_b0695","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.ccell.2022.08.003","article-title":"Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer","volume":"40","author":"Awad","year":"2022","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103125_b0700","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.cell.2020.08.053","article-title":"A phase Ib trial of personalized Neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer","volume":"183","author":"Ott","year":"2020","journal-title":"Cell"},{"issue":"22","key":"10.1016\/j.ctrv.2026.103125_b0705","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa1616288","article-title":"Tracking the evolution of non-small-cell lung cancer","volume":"376","author":"Jamal-Hanjani","year":"2017","journal-title":"N Engl J Med"},{"issue":"7528","key":"10.1016\/j.ctrv.2026.103125_b0710","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nature14001","article-title":"Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing","volume":"515","author":"Yadav","year":"2014","journal-title":"Nature"},{"issue":"7662","key":"10.1016\/j.ctrv.2026.103125_b0715","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2026.103125_b0720","doi-asserted-by":"crossref","first-page":"13404","DOI":"10.1038\/ncomms13404","article-title":"Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry","volume":"7","author":"Bassani-Sternberg","year":"2016","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103125_b0725","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","article-title":"Allele-specific HLA loss and immune escape in lung cancer evolution","volume":"171","author":"McGranahan","year":"2017","journal-title":"Cell"},{"issue":"7549","key":"10.1016\/j.ctrv.2026.103125_b0730","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nature14426","article-title":"Mutant MHC class II epitopes drive therapeutic immune responses to cancer","volume":"520","author":"Kreiter","year":"2015","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103125_b0735","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2016.03.012","article-title":"Expansion and Activation of CD103(+) dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition","volume":"44","author":"Salmon","year":"2016","journal-title":"Immunity"},{"issue":"7662","key":"10.1016\/j.ctrv.2026.103125_b0740","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103125_b0745","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrc3258","article-title":"Cancer immunotherapy via dendritic cells","volume":"12","author":"Palucka","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"6230","key":"10.1016\/j.ctrv.2026.103125_b0750","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103125_b0755","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.it.2017.05.006","article-title":"Integrating next-generation dendritic cell vaccines into the current cancer immunotherapy landscape","volume":"38","author":"Garg","year":"2017","journal-title":"Trends Immunol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103125_b0760","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/cr.2016.157","article-title":"Dendritic cell-based immunotherapy","volume":"27","author":"Sabado","year":"2017","journal-title":"Cell Res"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103125_b0765","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines - a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103125_b0770","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1016\/j.molonc.2015.10.016","article-title":"In situ vaccination: cancer immunotherapy both personalized and off-the-shelf","volume":"9","author":"Hammerich","year":"2015","journal-title":"Mol Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103125_b0775","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nrmicro2240","article-title":"Viruses as vaccine vectors for infectious diseases and cancer","volume":"8","author":"Draper","year":"2010","journal-title":"Nat Rev Microbiol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000393?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000393?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T23:20:35Z","timestamp":1779232835000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737226000393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":155,"alternative-id":["S0305737226000393"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103125","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoantigen-based dendritic cell vaccines in lung cancer: overcoming immunosuppressive barriers for durable antitumor immunity","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103125","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103125"}}